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naire (HAQ)Abstract Background: Programmed cell death-1 (PD-1) is an immunoreceptor that negatively regu-
lates antigen receptor signaling and plays a critical role in the immunoregulation of autoimmune diseases.
Aim of the work: This study aimed to measure the plasma and synovial ﬂuid levels of soluble pro-
grammed death-1(sPD-1) in rheumatoid arthritis (RA) patients and to correlate them with the clinical
and laboratory characteristics, disease activity, functional status and radiological severity.
Patients and methods: We measured sPD-1 in the plasma (n= 60) and synovial ﬂuid (SF) samples
(n= 24) from 60 RA patients and in the plasma from healthy control (n= 30). In the patients, dis-
ease activity score using 28 joint counts (DAS28) and the health assessment questionnaire (HAQ)
score were assessed; immunoglobulin-M rheumatoid factor (IgM-RF) titer, anti-cyclic citrullinated
peptide (anti-CCP) antibodies titer and C-reactive protein (CRP) levels were measured and total Sharp
score calculated.
Results: In RA patients both plasma and SF sPD-1 levels (1416.9 ± 1037.9 pg/ml and
1503.9 ± 1129.48 pg/ml respectively) were highly signiﬁcantly increased compared to its plasma level
in the healthy control (165 ± 26.11 pg/mL) (p< 0.001). In RA patients, the plasma and SF levels of
sPD-1 signiﬁcantly correlated with DAS28 (r= 0.52 and 0.58 respectively, p< 0.05), HAQ
scores (r= 0.48 and 0.51 respectively, p< 0.05) and anti-CCP titers (r= 0.55 and 0.58 respectively,
p< 0.05).
Conclusions: Rheumatoid arthritis patients have signiﬁcantly elevated plasma and synovial levels of
sPD-1 that remarkably correlated with the DAS28 suggesting that it could be a useful marker to reﬂect
RA disease activity. The considerable association of sPD-1 with autoantibodies production implies a
possible role in the pathogenesis of RA.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Rheumatoid arthritis (RA), one of the most common systemic
autoimmune diseases, is characterized by chronic joint inﬂam-
mation and subsequent joint destruction [1]. The pathogenesis
of RA is multifactorial with contributions from genetic poly-
morphisms, immune dysfunction, oxidative stress, apoptosis,
infectious, environmental and hormonal factors [2–7]. Over-
expression and dysfunction of clusters of differentiation may
result in the development of autoimmune diseases [8].
The cluster of differentiation 4+(CD4+) T-cells is responsi-
ble for the production of several pro-inﬂammatory cytokines,
promotion of inﬂammation, activation of macrophages and
osteoclasts, and subsequent joint destruction [9]. Costimula-
tory molecules are members of a growing family of receptors
and ligands that play an important role in controlling and reg-
ulating the immune response, some of them are critical for the
activation of T cells by providing the second signal to T-cell
receptor (TCR) cross-linking whereas others, such as cytotoxic
T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-
1), and programmed death-ligand1 (PD-L1), are thought to
down-regulate T cell response [10].
PD-1 is a member of the CD28 family that plays a role in
regulating T-cell activation and tolerance. PD-1 is inducibly
expressed on T cells, B cells, macrophages, and natural killer
T cells after activation [11]. PD-1 has two ligands, PD-L1
and PD-L2, which have different expression patterns. PD-L1
is broadly expressed in both hematopoietic and non hemato-
poietic tissues and is upregulated on activated T cells, B cells,
macrophages, and DCs upon stimulation, while PD-L2 expres-
sion is restricted to activated macrophages and dendritic cells
(DCs) [12]. Cross-linking of PD-1 by its ligands, PD-L1 and
PD-L2, leads to the down-regulation of T-cell responses by
mediating programmed cell death and inhibiting cell prolifera-
tion [13]. Upregulation of PD-1 and PD-L1 is dependent on
inﬂammatory cytokines such as interferon-gamma (IFN-c)
and members of the common c-chain family [14]. In a similar
manner to CTLA-4, PD-1 functions by inhibiting T-cell
receptor (TCR)-mediated events such as cell proliferation
and survival, and also interleukin-2 (IL-2), tumor necrosis
factor-alpha (TNF-a), and IFN-c production [15].
The critical role for PD-1 in immune regulation is high-
lighted by recent gene disruption studies demonstrating that
strain-speciﬁc phenotypes, such as PD-1-deﬁcient C57BL/6
mice, develop lupus-like autoimmune proliferative arthritis
and glomerulonephritis with IgG3 deposition [16], whereas
deﬁciency of PD-1 in BALB/c mice results in a severe
autoimmune dilated cardiomyopathy followed by death due
to congestive heart failure [17].
The mechanism of action, as to how co-stimulatory mole-
cules are exactly involved in the activation and regulation of
inﬂammatory autoimmune T-cells, remains elusive. Little is
known about the role of co stimulatory molecules in many
human autoimmune conditions [18]. For example, in RA, it
is unclear as to how the peripheral immune system that inte-
grates various regulatory mechanisms and networks fails to
regulate persistent synovial T cell activation and inﬂammation.
This may be reasoned to the overexpression of positive regula-
tors, i.e., co stimulatory molecules capable of augmenting
T cell activation (e.g., CD28) in synovial T cells and
macrophages, and/or aberrant expression of those negativeregulators (e.g., CTLA-4, PD-1) or functional antagonism of
these molecules by soluble factors [19,20].
This study aimed to measure the plasma and synovial ﬂuid
(SF) levels of soluble programmed death-1(sPD-1) in rheuma-
toid arthritis (RA) patients and to correlate them with the clin-
ical and laboratory characteristics, disease activity, functional
status and radiological severity.
2. Patients and methods
2.1. Participants
Sixty patients, fulﬁlling the 2010 ACR-EULAR classiﬁcation
criteria for RA [21] were recruited from the in-patients and
out-patients’ clinic of the Rheumatology and Rehabilitation
department of Benha university hospitals between January
and October 2014. Thirty age and sex matched apparently
healthy individuals from the hospital personnel, undergradu-
ates; medical and nursing staffs were also included as a con-
trol group. Patients’ evaluation included full history taking
with recording of the disease duration, thorough physical
examination, with particular focus on the pattern of joint
involvement, the presence of nodules and other extra-articu-
lar features and ongoing medications. Disease activity using
28 joint counts (DAS28) [22] and Health Assessment Ques-
tionnaire (HAQ) [23] were assessed in all patients. X-rays
(postero-anterior view) of the hands and feet were obtained
for all patients and were scored by the total sharp score sys-
tem [24]. The local ethics committee of our institution (Benha
University, Faculty of Medicine) approved the study and all
participants gave a written informed consent before being
enrolled in this study.
2.2. Laboratory investigations
Blood specimens were collected after an overnight fasting ana-
lyzed for complete blood count (CBC), erythrocyte sedimenta-
tion rate (ESR) by Westergren’s method [25] in mm/hour,
C-Reactive protein (CRP), Rheumatoid factor (RF) and
anti-cyclic citrullinated peptide (anti-CCP) antibodies.
2.2.1. Measurement of plasma and synovial ﬂuid levels of sPD-1
The sPD-1 levels were measured in the plasma collected from
all RA patients and controls, in addition to the SF samples
that were obtained from 24 of the RA patients who had knee
effusion at the time of the study. All plasma samples were col-
lected in heparinized tubes and stored at 80 C until analysis.
Synovial ﬂuid samples were centrifuged and the supernatants
carefully collected and stored at 80 C until analysis. Assay
of sPD-1 was made by the enzyme linked immunosorbent
assay (ELISA) technique using the kit supplied from (My bio-
source, San Diego, California, USA) Human Soluble Pro-
grammed Death-1 (SPD-1) ELISA Kit Cat. No:
MBS026745. The assay procedures were followed according
to the manufacturer’s instructions. The detection range is
125 pg/ml–4000 pg/ml.
Statistical analysis: The collected data were analyzed using
SPSS version 16. Categorical data were presented as number
and percentages while continuous variables were presented as
mean and SD if parametric, and as median and range if non
Figure 1 Comparison between plasma and synovial ﬂuid sPD-1
levels of the rheumatoid arthritis (RA) patients and the plasma
sPD-1 level in the healthy control.
Signiﬁcance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients 167parametric. Chi square, Z-test, Mann Whitney U test, Krus-
kal–Wallis test and Spearman’s correlation coefﬁcients were
used as tests of signiﬁcance. Two sided p-value < 0.05 was
considered signiﬁcant.
3. Results
Sixty RA patients (ages ranged from 20 to 65 years) with a
mean of 41.3 ± 13.3 years and thirty age and sex matched
apparently healthy control (ages ranged from 19 to 63 years)
with a mean of 40 ± 13.1 years were included in the study.
Patients’ clinical and laboratory features are shown in Table 1.
The mean plasma and synovial sPD-1 levels in the RA patients
(1416.9 ± 1037.9 and 1503.9 ± 1129.48 pg/ml respectively)
showed a highly statistically signiﬁcant (p< 0.001) increase
as compared to the mean plasma levels in the control
(165 ± 26.11 pg/ml). (Fig. 1). Although the synovial ﬂuid
sPD-1 level was higher than in the plasma of the RA patients,
the difference showed no statistical signiﬁcance (p> 0.05).
Regarding RF positivity, the mean sPD-1 plasma level in
the seropositive RA patients (1581 ± 1069 pg/ml) showed a
highly statistically signiﬁcant increase (p< 0.001) compared
to the seronegative patients (760.4 ± 551.7 pg/ml) but there
was no statistically signiﬁcant difference (p> 0.05) between
the mean sPD-1 synovial ﬂuid levels of the seropositive and
seronegative RA patients (1503.9 ± 1129.48 and 1416.9 ±
1037.9 pg/ml respectively) (Table 2).
Plasma sPD-1 levels showed a statistically signiﬁcant corre-
lation with the ESR (r= 0.45, p< 0.05), CRP level (r= 0.57,
p< 0.05), RF titers (r= 0.55, p< 0.05), anti-CCP titers
(r= 0.55, p< 0.05), DAS28 scores (r= 0.52, p< 0.05) and
HAQ (r= 0.48, p< 0.05). Synovial sPD-1 levels showed a
statistically signiﬁcant correlation with the ESR (r= 0.61,
p< 0.05), CRP (r= 0.55, p< 0.05), anti-CCP titers (r=
0.58, p< 0.05), DAS28 (r= 0.58, p< 0.05) and HAQ
(r= 0.51, p< 0.05) (Table 3). There was a highly statistically
signiﬁcant correlation between both plasma and SF sPD-1
levels in the RA patients (r= 0.73, p< 0.001).
4. Discussion
It has been suggested that PD-1 possibly contributes to the
pathogenesis of RA especially as the PD-1 gene is signiﬁcantlyTable 1 Clinical and laboratory characteristics, disease
activity, radiological severity and functional disability of the
rheumatoid arthritis (RA) patients (n= 60).
Characteristic Mean ± SD
Disease duration (years) 7.7 ± 4.6
Tender joints (No) 10.5 ± 3.1
Swollen joints (No) 8.3 ± 2.4
Morning stiﬀness (min) 84.2 ± 26.3
ESR (mm/1st h) 53.5 ± 17.6
CRP (mg/dl) 28.1 ± 14.5
DAS-28 4.8 ± 0.8
Total sharp score 26.2 ± 24.9
HAQ 1.08 ± 0.9
No, number; ESR, erythrocyte sedimentation rate; CRP, C reactive
protein; DAS, disease activity score; HAQ, health assessment
questionnaire.associated with RA susceptibility [26]. Contrarily, in another
study it has been demonstrated that PD-1 ligand gene
polymorphisms were not associated with susceptibility to RA
[27]. T cell activation and function are critically regulated by
positive and negative co-stimulatory molecules. Aberrant
expression and function of co-stimulatory molecules have been
associated with persistent activation of self-reactive T cells in
autoimmune diseases such as RA [3]. PD-1 and its ligand,
are known to play an important immunoregulatory role by
controlling the development of immune effector cells [28,29].
The precise function of the soluble form of PD-1 is not well
described, and sPD-1 has been reported to exhibit both
‘functional antagonism’ [30] as it functionally blocks and
inhibits the immune regulatory effect of membrane bound
PD1 on T cell activation and attenuates the PD-1 pathway
leading to worsening the disease; and ‘agonism’ as others
claimed that sPD-1 functions like the membrane form, exhib-
iting immune regulation by limiting TCR induced events [31].
In our study both plasma and SF sPD-1 levels were statis-
tically signiﬁcantly elevated in the RA patients than in the
plasma level in the healthy controls, and these levels signiﬁ-
cantly correlated with the clinical and laboratory parameters
of disease activity, DAS 28 and HAQ. Our results conﬁrmed
that results of others which found an elevated plasma and
synovial sPD-1 level in RA patients than in the controls
[10,32].
We found that both plasma and SF sPD-1 are signiﬁcantly
correlated to each other and this increased SF sPD-1 level
indicates that sPD-1 in the given compartment reﬂects cellular
expression. PD-1 expression is upregulated by low-afﬁnity
ligation of the TCR, and these low-afﬁnity peptides are
overexpressed in the RA synovium conﬁrming the ideal
conditions in the joint for PD-1 up-regulation [33].
The signiﬁcant correlation between sPD1 levels and the dis-
ease activity that had been found in our study is against the
original hypothesis because of an obvious contradiction
between over-expression of co stimulatory molecules capable
of down-regulating T cell response and persistent activation
of self-reactive T cells known to exist in rheumatoid synovium.
It had been suggested by Wan et al. [10] to revise the precise
role of co-stimulatory molecules in persistent T cell activation
Table 3 Correlations between plasma and synovial ﬂuid sPD-
1 levels and different variables in rheumatoid arthritis (RA)
patients.
Variable in RA patients sPD-1 (pg/ml)
Correlation coeﬃcient (r) Plasma SF
Age (years) 0.1 0.13
Disease duration (years) 0.01 0.18
Morning stiﬀness (min) 0.24 0.25
ESR (mm/1st h) 0.45* 0.61*
C-reactive protein (mg/dl) 0.57* 0.55*
Rheumatoid factor 0.55* 0.39
Anti-CCP 0.55* 0.58*
DAS-28 0.52* 0.58*
HAQ 0.48* 0.51*
Total sharp score 0.29 0.36
ESR, erythrocyte sedimentation rate; CCP, cyclic citrullinated
peptide; sPD-1, soluble programmed death-1; DAS, disease activity
score; HAQ, health assessment questionnaire.
* Signiﬁcant p< 0.05.
Table 2 Comparison between the sPD-1 plasma and synovial ﬂuid levels in seropositive and seronegative rheumatoid arthritis (RA)
patients.
sPD-1 (pg/ml) Rheumatoid arthritis patients (n= 60) t test p
Mean ± SD Sero + ve RF (n= 48) Sero ve RF (n= 12)
Plasma 1581 ± 1069 760.4 ± 551.7 1.21 <0.001
Synovial ﬂuid 1507 ± 1166.7 (n= 19) 1494 ± 1100 (n= 5) 0.19 >0.05
sPD-1, soluble programmed death-1; RF, rheumatoid factor.
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known inhibitory properties of these negative regulators.
Fontenot et al. [34] suggested that it is conceivable that persis-
tent T cell activation and overly produced pro-inﬂammatory
cytokines are seen as a danger signal by the immune system
that reacts by selectively up-regulating the expression of nega-
tive costimulatory molecules. Apart from T-cell-associated
cytokines, low-afﬁnity ligation of the TCR will also result in
increased expression of PD-1, and the inhibitory effect of
PD-1 is therefore dependent on the degree of T-cell activation
[13]. This possible mechanism may have a broader spectrum to
include negative regulators of other family or network, such as
Foxp3 and Fas/Fas ligand. It was further evident that both
soluble PD-1 and PD- L1, in a form of recombinant fusion
protein, are able to effectively block the function of mem-
brane-bound PD-1 and PD-L1 at a concentration range of
20 ng/ml in the in vitro experimental system. It appears that
higher concentrations of recombinant fusion proteins are
required to affect synovial T cell function in the system than
the concentration of PD-1 and PD-L1 seen in RA SF [10].
Again, in contrast to our results, in the study of Li et al. [35]
it has been found that levels of sPD-1 were downregulated in
RA cases and negatively correlated with the increased CRP
and disease activity score.
Grisen et al. [32] suggested a relationship between the pro-
duction of autoantibodies and the shedding of PD-1, this was
conﬁrmed in our study as we found that plasma sPD-1 is
strongly associated with the autoantibodies IgM-RF andanti-CCP and the SF sPD-1 with anti-CCP raising questions
about the role of sPD-1 in autoantibody formation.
We found no signiﬁcant correlation between the plasma or
synovial sPD-1 levels and radiographic total sharp score. This
was in contrast to that found by Grisen et al. [32] who
demonstrated an inverse association between the relative
change in sPD-1 and radiographic progression and showed
that sustained high levels of sPD-1 after treatment initiation
were associated with less radiographic progression in the future.
Grisen et al. [32] explained that the T-cell co-stimulatory
factors PD-1 act as CTLA-4, both can interfere with osteo-
clastogenesis but not with osteoclast function and the surplus
of sPD-1 could modulate the activation of the T cells, decrease
osteoclastogenesis and thereby modulate osteoclast function
and on that base they claimed that inﬂammation and bone
erosion can be independent events.
In conclusion, RA patients have signiﬁcantly elevated levels
of plasma and SF sPD-1 that are correlated with DAS28 sug-
gesting sPD-1 to be a useful marker that reﬂects RA disease
activity. The considerable association of sPD-1 with autoanti-
bodies production implies a possible role in the pathogenesis
of RA.
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